Mutation and gender-specific risk in type 2 long QT syndrome: Implications for risk stratification for life-threatening cardiac events in patients with long QT syndrome
Background
Men and women with type 2 long QT syndrome (LQT2) exhibit time-dependent differences in the risk for cardiac events. We hypothesized that data regarding the location of the disease-causing mutation in the KCNH2 channel may affect gender-specific risk in LQT2.
Objective
This study sought to risk-stratify LQT2 patients for life-threatening cardiac events based on clinical and genetic information.
Methods
The risk for life-threatening cardiac events from birth through age 40 years (comprising aborted cardiac arrest [ACA] or sudden cardiac death [SCD]) was assessed among 1,166 LQT2 male (n = 490) and female (n = 676) patients by the location of the LQTS-causing mutation in the KCNH2 channel (prespecified in the primary analysis as pore-loop vs. non–pore-loop).
Results
During follow-up, the cumulative probability of life-threatening cardiac events years was significantly higher among LQT2 women (26%) as compared with men (14%; P <.001). Multivariate analysis showed that the risk for life-threatening cardiac events was not significantly different between women with and without pore-loop mutations (hazard ratio 1.20; P =.33). In contrast, men with pore-loop mutations displayed a significant >2-fold higher risk of a first ACA or SCD as compared with those with non–pore-loop mutations (hazard ratio 2.18; P = .01). Consistently, women experienced a high rate of life-threatening events regardless of mutation location (pore-loop: 35%, non–pore-loop: 23%), whereas in men the rate of ACA or SCD was high among those with pore-loop mutations (28%) and relatively low among those with non–pore-loop mutations (8%).
Conclusion
Combined assessment of clinical and mutation-specific data can be used for improved risk stratification for life-threatening cardiac events in LQT2.
Keywords: Long QT syndrome, Pore-loop mutations, Sudden cardiac death, Gender
Abbreviations: ACA, aborted cardiac arrest, ECG, electrocardiogram, ICD, implantable cardioverter-defibrillator, LQTS, long QT syndrome, LQT2, long QT syndrome type 2, QTc, corrected QT, SCD, sudden cardiac death
To access this article, please choose from the options below
Conflict of interests/disclosure: Dr. Ackerman is a consultant for Biotronik, Boston Scientific, Medtronic, PGx Health, and St. Jude Medical; and has intellectual property in PGx Health. Dr. Kaufman receives grant support from CardioDx, Cambridge Heart Inc., and St. Jude Medical. All other authors have reported that they have no relationships to disclose.
This work was supported by research grants HL-33843 and HL-51618 from the National Institutes of Health and by a research grant from GeneDx to the Heart Research Follow-Up Program in support of the LQTS Registry.
PII: S1547-5271(11)00361-4
doi:10.1016/j.hrthm.2011.03.049
© 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
